CD4+ and CD8+ T cells play a central role in a HDM driven model of allergic asthma
- 2.1k Downloads
The incidence of asthma is increasing at an alarming rate and while the current available therapies are effective in the majority of patients they fail to adequately control symptoms at the more severe end of the disease spectrum. In the search to understand disease pathogenesis and find effective therapies animal models are often employed. As exposure to house dust mite (HDM) has a causative link, it is thought of as the allergen of choice for modelling asthma.
The objective was to develop a HDM driven model of asthmatic sensitisation and characterise the role of key allergic effector cells/mediators.
Mice were sensitised with low doses of HDM and then subsequently challenged. Cellular inflammation, IgE and airway responsiveness (AHR) was assessed in wild type mice or CD4+/CD8+ T cells, B cells or IgE knock out mice.
Only those mice sensitised with HDM responded to subsequent low dose topical challenge. Similar to the classical ovalbumin model, there was no requirement for systemic alum sensitisation. Characterisation of the role of effector cells demonstrated that the allergic cellular inflammation and AHR was dependent on CD4+ and CD8+ T cells but not B cells or IgE. Finally, we show that this model, unlike the classic OVA model, appears to be resistant to developing tolerance.
This CD4+/CD8+ T cell dependent, HDM driven model of allergic asthma exhibits key features of asthma. Furthermore, we suggest that the ability to repeat challenge with HDM means this model is amenable to studies exploring the effect of therapeutic dosing in chronic, established disease.
KeywordsAsthma T cells Animal model Lung Inflammation
20 mg/ml aluminium hydroxide and 20 mg/ml
area under the curve
bronchoalveolar lavage fluid
bovine serum albumin
cluster of differentiation
enzyme-linked immunosorbent assay
forced expiratory volume in 1 s
house dust mite
phosphate buffered saline
standard error of the mean
whole body plethysmograph
Asthma is a chronic inflammatory disease of the airways characterised not only by cellular infiltration into the airways, but also by an accompanying increase in the sensitivity and response to contractile agents (airway hyperresponsiveness-AHR) and to allergen exposure (early and late asthmatic responses) [1, 2]. The global prevalence of asthma is increasing [3, 4], and the symptoms are often inadequately controlled . Pre-clinical models which closely mimic clinical features of asthma are useful to improve our understanding of the mechanisms driving the disease and thereby the ability to identify novel therapeutic targets.
Rodent models of experimental allergic asthma to date have contributed greatly to our current understanding of the pathogenesis of the disease. However, one of the most widely used aeroallergens in model development, ovalbumin (OVA), is rarely implicated in clinical asthma and is often used in more acute challenge protocols due to the development of inhalation tolerance and a diminishing or complete abrogation of the airway inflammatory response following multiple challenges [6, 7, 8, 9]. Conventional rodent OVA-models are thought to require co-administration of an adjuvant to establish successful sensitisation. Therefore OVA may not be the most disease relevant allergen. In contrast, exposure to house dust mite (HDM), the major source of allergen in house dust, has been shown to play an important role in asthma and also in other allergic diseases such as dermatitis and rhinitis [10, 11, 12, 13]. In the clinic it has been shown that sensitisation to HDM is a strong predictor for asthma and there is a correlation between the level of HDM exposure and sensitisation [10, 11]. Because of its clear relevance to human disease, HDM has in recent years become the allergen of choice in the development of animal models of asthma often relying on chronic topical exposure without developing tolerance [14, 15, 16, 17, 18, 19]. However, it is possible that in these models part of the inflammatory response is due to innate mechanisms in response to repeat inflammatory insults rather than allergic mechanisms [20, 21]. We propose that to fully understand the disease phenotype it is important to characterise the different stages of the inflammatory response in vivo. Therefore the aim of this study was to initially demonstrate this acute innate response and briefly investigate the mechanisms involved (i.e. Dectin 1/2 and TLR 2/4 receptors have been linked to this response) and then to go on to develop a murine HDM-driven allergic model based around a separate sensitisation and challenge protocol. Furthermore we also investigated the role of key allergic effector cells in features of allergic asthma using this model. We additionally aimed to compare key features of this model to a standard OVA-model and investigate its potential for chronic allergen exposures without the associated tolerance. We suggest the data presented here will help to elucidate the mechanisms driving the inflammation observed after acute and chronic HDM exposure and present targets for possible future therapeutic intervention.
Male C57BL/6 mice (16–20 g) were obtained from Harlan UK Limited (Bicester, UK) and housed with food and water supplied ad libitum for at least 5 days before beginning treatments. Genetically modified mice (knockout, KOs) were back-crossed at least 8 times and bred alongside the wild type mice: Dectin-1 -/-, Dectin-2 -/-, TLR2 -/-, TLR4-/-, B cell-/- (JHT mice), CD4 T-cell -/-, CD8 T-cell -/- and IgE -/-. Wild-type (WT) mice on a C57bl/6 background were bred in-house to be used as comparators for the KO animals. Protocols were approved by the Animal Welfare and Ethical Review Body (Approval No. PPL 70/7212), and strictly adhered to the Animals (Scientific Procedures) Act 1986 UK Home Office guidelines and performed according to the ARRIVE guidelines. Dectin-1 and Dectin-2 KO mice were donated by Professor Yoichiro Iwakura, Tokyo University; TLR2, TLR4, B cell, CD4+ T cell, CD8+ T cell and IgE KO mice were obtained from the Swiss Immunological Mouse Repository (SwimMR).
House dust mite extract
Purified HDM extract from Dermatophagoides pteronyssinus (Der p; lot number 124632; GREER laboratories, USA) with a known content of Der p1 (12.76 μg/mg dry weight) was used in these experiments. The doses of HDM used in this manuscript refer to the amount of Der p1 delivered.
All agents were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated.
Effect of acute house dust mite
WT mice, TLR2, TLR4, Dectin-1 and Dectin-2 KO mice were anaesthetised (4 % Isoflurane in oxygen for 3 min, Abbott Laboratories, UK) and challenged with vehicle (saline) or HDM extract (25 μg, intratracheally – selected from a previous dose response study). A second group of WT mice was challenged with protease inactivated HDM (by heating to 65 °C for 30 min as previously described [20, 22]). WT mice were culled with an overdose of sodium pentobarbitone (200 mg/kg, i.p.; Merial, France) 2, 6, 24, 48, 72 or 96 h after challenge and KO mice at 72 h after challenge. Inflammatory cell recruitment in the lung was assessed. Briefly, the trachea was cannulated and bronchoalveolar lavage fluid (BALF) was obtained via lavage with 0.3 ml RPMI 1640 (Invitrogen, UK) 3times. The lavage fluid was pooled. BALF total white blood cell counts were performed using an automated cell counter (Sysmex F-820, Sysmex UK Ltd). Cytospins of BALF was prepared by centrifugation of 100 μl in a cytospin (Shandon, UK) at 700 RPM for 5 min. Slides were subsequently fixed and stained using a Hema-Tek 2000 (Ames Co., Elkhart, IN) with a modified Wright-Giemsa stain. Differential counts on 200 cells were performed following standard morphological criteria and the percentage of eosinophils, neutrophils and lymphocytes were determined. After lavaging the airway the lung was removed and the weight recorded. The lung tissue was then finely chopped and underwent an enzymatic digest to extract white blood cells. Subsequent analysis of white blood cell numbers was performed as described above.
Development of an allergic HDM driven asthma model
Selection of sensitising dose and sensitisation route
To determine an optimum sensitisation dose and route a regimen adapted from a previously described OVA model  was used. Topically sensitised WT mice received intranasal (i.n.) saline or HDM (50 μl; 0.005–500 μg/kg) on day 0 and 14. Systemically sensitised WT mice received intraperitoneal (i.p.) saline, Alum (diluted 1:1 with saline; Pierce Biotechnology Inc, USA), HDM (0.005–500 μg/kg,) or Alum with HDM (0.005–500 μg/kg) on day 0 and 14. On day 21, following a sodium pentobarbitone (200 mg/kg, i.p.) overdose, heparinised blood samples were taken by cardiac puncture. Plasma total IgE and IgG1, HDM specific IgE and IgG1 levels were measured by ELISA.
Selection of challenging dose
Male C57bl/6 mice were sensitised on day 0 and 14 with saline in Alum or HDM in Alum (0.5 μg/kg, i.p.). Mice were challenged i.n. with saline or HDM (50 μl; 0.125–125 μg/kg) on days 24–26. Mice were lavaged 3 days after the last challenge. BALF total and differential white blood cell counts were performed as described above.
Determining the need for Alum – HDM and OVA models
Male C57bl/6 mice were sensitised on day 0 and 14 with saline, Alum, HDM (0.5 μg/kg, i.p.) or Alum plus HDM (0.5 μg/kg) and challenged i.n. once daily on days 24–26 with saline or HDM (50 μl; 1.25 μg/kg). BALF was collected 3 days after the last challenge and inflammatory cell burden determined.
In a parallel group of mice sensitised with HDM only (no alum) 3 days after the final HDM challenge, airway responsiveness to 5-HT was assessed as changes in enhanced pause (Penh – conscious animals) or airway resistance (in anaesthetised animals).
Does topical challenge lead to sensitisation?
Male C57bl/6 mice were give saline or HDM (i.n. or i.p.) and subsequently challenged with saline or HDM as described above. 3 days after the final challenge lungs were lavaged and inflammatory cell burden determined.
Male C57bl/6 mice were sensitised with saline, OVA (10 μg/100 μl i.p.), Alum plus saline or Alum plus OVA (10 μg/100 μl i.p.) on days 0 and 14 and then challenged i.n. with saline or OVA (50 μg) on days 24–26. Three days after the final OVA challenge airway responsiveness to 5-HT was assessed as changes in enhanced pause (Penh – conscious animals). BALF was collected for assessment of inflammatory cell burden, plasma samples were harvested and levels of total and OVA-specific IgE assessed by ELISA.
Chronicity of the HDM model
Male C57bl/6 mice were sensitised on day 0 and 14 with saline or HDM (0.5 μg/kg, i.p.) and challenged i.n. with saline or HDM (50 μl; 1.25 μg/kg) 3 times a week on consecutive days (starting on day 24) for 5 weeks. 3 days after the final HDM challenge airway responsiveness to 5-HT and the levels of cellular inflammation in BALF were assessed as described above. Lung tissue was collected for pathological assessment (inflammatory score, PAS staining, collagen deposition and ASM area assessment). Briefly, lung tissue was fixed with formalin and embedded in paraffin and multiple 4 uM thick sections cut.
Slides were stained with aematoxylin and eosin (H + E) and placed on the stage of an Olympus BX51 fluorescence microscope coupled to a QICAM 1394 camera and colour images were taken. Analysis was done by a trained person blinded to prior treatment. Six random areas were selected and each area was scored for inflammatory burden (0 to 5) and the data was averaged for each slide and then for each n number in the group.
Mucus production assessment
The slides were stained with Periodic acid–Schiff (PAS – mucus appears a bright purple-magenta colour). Assessment was performed using the protocol outlined above.
Smooth Muscle Area (SMA)
Alpha actin was stained using a primary antibody (Ab-5694, Abcam) and a secondary antibody (Ab 111-066-003, Jackson Labs). The staining was revealed using the peroxydase kit from vector laboratories (DAB Peroxidase (HRP) Substrate Kit) without Nickel (alpha actin stained in brown). The slides were counterstained with haematoxylin (blue). Analysis was performed as described above and expressed as SMA per airway perimeter.
Collagen deposition assessment
Slides were stained with Sirius Red and counter stained with haematoxylin. Slides were mounted on an inverted microscope (Zeiss AxioVert 200 M) equipped with a circularly polariser and coupled to a Hamamatsu EM-CCD C9100-02 camera. Images were taken in grey tone under polarised light were collagen stained with Sirius red appears brightly. Analysis was performed as above and expressed as an area of collagen per airway perimeter.
Characterisation of the allergic HDM driven asthma model
Profiling a clinically relevant therapy
Mice were sensitised on day 0 and 14 with saline or HDM (0.5 μg/kg) i.p. and challenged i.n. with saline or HDM (50 μl; 1.25 μg/kg) on days 24–26. Mice received an oral dose of vehicle (0.5 % methylcellulose plus 0.2 % tween 80 in water, 10 ml/kg) or budesonide (3 mg/kg) twice per day on days 24–28 and also a final dose on day 29. 3 days after the final HDM challenge airway responsiveness to 5-HT and the levels of cellular inflammation in BALF were assessed as described above.
Determine the role of key allergic effector cells/mediator
WT, CD4+ T cell, CD8+ T cell, B cell or IgE KO mice were sensitised on day 0 and 14 with saline or HDM (0.5 μg/kg, i.p.) and challenged i.n. with saline or HDM (50 μl; 1.25 μg/kg) on days 24–26. 3 Days after the final HDM challenge airway responsiveness to 5-HT and the levels of cellular inflammation in BALF were assessed as described above.
Data analysis and statistics
Data was expressed as mean ± S.E.M of n observations. A p value < 0.05 was taken as statistically significant, the test used is indicated in the figure legends.
Acute HDM challenge
Development of an allergic HDM driven asthma model
Selection of optimum sensitising route and dose
Selection of optimum challenging dose
Does topical challenge lead to sensitisation?
As we show in Fig. 2, in our hands intranasal sensitisation did not result in measurable changes in the levels of plasma IgE. The current trend in HDM model development has been to adopt experimental protocols employing repeated topical intranasal sensitisation with HDM followed by repeated topical intranasal HDM challenge, rather than the more traditional approach with distinct sensitisation and challenge phases. In our hands however, intranasal HDM challenge in mice topically sensitised with HDM did not result in an inflammatory cell influx into the BALF (Additional file 3: Figure S3). Mice subjected to our systemic i.p. sensitisation and topical i.n. challenge protocol, as shown previously (Fig. 3), mounted a robust inflammatory response as measured by increases in the number of eosinophils, neutrophils and lymphocytes in BALF (Additional file 3: Figure S3).
Determining the need for Alum
Airway function in HDM model
Chronic HDM exposure
Characterisation of the allergic HDM driven asthma model
Profiling a clinically relevant therapy
Determine the role of key allergic effector cells/mediators
Pre-clinical models closely mimicking the cardinal features of asthma are useful in understanding the mechanisms driving the disease and can help in identifying novel therapeutic targets. Traditional models of allergic asthma involve the use of OVA along with adjuvants such as Alum and have been profiled extensively. Yet, these models have limitations. On the other hand, HDM is increasingly being used as a disease-relevant antigen in rodent models of allergic airway inflammation since it does not require an adjuvant and is not linked to the development of inhalation tolerance [15, 16, 17, 18]. However, previous studies have suggested that part of the airway inflammation observed in response to topical HDM is due to innate rather than allergic mechanisms [20, 21]. Therefore, to fully understand the disease phenotype and extrapolate in vivo data to the clinic, we suggest it is necessary to clearly distinguish between the events underlying sensitisation and challenge, and characterise all stages of the allergic inflammatory response in vivo. In the present study, we describe an in vivo mouse model of HDM-induced allergic asthma with a distinct sensitisation and challenge phase characterised by allergen induced airway inflammation and AHR dependent on CD4+ and CD8+ T cells, but not B cells or IgE. This inflammation and AHR was sensitive to treatment with systemic steroids showing the model to be relevant to clinical asthma. In addition this model exhibits persistent airway inflammation and AHR following chronic exposure to the allergen.
A single topical exposure to HDM caused robust inflammatory cell recruitment into the mouse airway. Although the prominent cell type was neutrophils we could also detect an increase in eosinophils and lymphocytes (Fig. 1). This can be recapitulated in the rat  and thus far the mechanism underlying this innate response remains unclear. HDM extracts have been shown to contain various other contaminants capable of activating inflammatory pathways [33, 34, 35]. Our data exclude a role for HDM innate protease activity, TLR4 and Dectin-1 (Additional file 1: Figure S1) activation in this response despite previous studies implicating these factors in HDM-mediated inflammatory responses [24, 25, 26, 28], but show that there is a potential involvement of TLR2 and Dectin-2 (Additional file 1: Figure S1) in accordance with previous reports [27, 28, 29, 30]. Although this falls outside the scope of the current publication, we suggest that further investigation of this underlying mechanism driving acute HDM-induced inflammation will lead to a better understanding of animal models, and could potentially uncover disease relevant mechanisms involved in the pathogenesis of asthma.
This apparent innate inflammatory response to HDM could confound the understanding of mechanisms underlying asthma-like features in animal models and complicate extrapolation of results to the clinic. We therefore developed a HDM-driven murine model in which airway inflammation and AHR only occurred in animals which had been previously sensitised to HDM. Using direct comparison studies we demonstrated that Alum during the sensitisation stage was not required for the allergic airway inflammation and AHR observed in this HDM model (Figs. 4 and 5). This is a great advantage as it avoids the use of an exogenous adjuvant and more closely resembles the allergenic cocktail to which patients are exposed. HDM has been demonstrated to possess innate adjuvant capacity and as such the fact that an exogenous adjuvant was not required for successful sensitisation or for the development of allergic asthma following allergen exposure, is not surprising. Interestingly, we also show that an adjuvant was not required for the production of OVA-specific IgE or the induction of airway inflammation and AHR in an OVA-dependent murine model (Additional file 4: Figure S4 and Additional file 5: Figure S5). This is surprising when one considers current dogma and that the majority of published models suggest that the OVA model requires the use of a systemic adjuvant to induce allergic sensitisation. Despite being widely criticised for not being clinically relevant and although adjuvant-free OVA models have been described [36, 37, 38] adjuvant dependent OVA-models continue to be used in the field. It has been noted that OVA is contaminated with lipopolysaccharide which might account for some of its auto-adjuvant properties .
Our results also highlight the importance of choosing the appropriate route for allergen delivery. Although several murine models utilising systemic sensitisation have been described [40, 41], the majority of research groups that utilise HDM-driven murine models currently favour topical sensitisation rather than systemic routes [14, 15, 16, 17, 18, 19]. However, in contrast to these published models, this new HDM model uses systemic allergen sensitisation with a full HDM extract with all its associated contaminants without the need for an adjuvant. It is currently accepted that asthmatics become sensitised to HDM and other aeroallergens through the airways. However, several other mechanisms can lead to sensitisation and the development of allergic airways disease. Infants may have some features of allergy at birth through prenatal in-utero sensitisation [42, 43, 44]. In addition, in those atopic patients whereby atopic dermatitis is developed early on, followed by allergic rhinitis and subsequently atopic asthma later in life systemic sensitisation seems more likely, rather than sensitisation through airway exposure [45, 46, 47]. The fact that not every person exposed to HDM becomes sensitised and develops allergic asthma suggests that an animal model where allergen exposure only elicits a response in previously sensitised animals seems preferable. In contrast to reports that Balb/c mice can be primed to respond to HDM challenges via intranasal sensitisation  in our hands in this C57BL/6 murine model this did not occur (Fig. 2 and Additional file 3: Figure S3) and thus supports our use of systemic sensitisation during model development.
Due to the difficulty developing appropriate models capable of recapitulating key features of chronic asthma, the mechanisms underlying the chronicity of the disease have been far less investigated when compared to acute, immediate responses. The common allergen, OVA, frequently used in model development has been reported by many groups following chronic exposure protocols to result in inhalation tolerance and the abrogation of the inflammatory airway response [6, 7, 8, 9]. It has been suggested that intermittent allergen exposures over prolonged periods of time do not result in the development of tolerance [31, 32]. Our data show that the administration of HDM over the course of 5 weeks in the absence of exogenous adjuvants does not lead to tolerance but a robust inflammatory response in HDM sensitised animals characterised by persistent airway eosinophilic, neutrophilic and lymphocytic airway infiltration accompanied by AHR to 5-HT (Fig. 6). It is plausible that the robust allergic response in our model is attributable to the non-continuous allergen exposure protocol. These results parallel data collected in those models employing chronic topical HDM challenges [18, 19, 20, 21, 22, 23] and highlight the feasibility of using HDM to model chronic disease symptoms and the potential of the model to be used to assess the effect of new therapeutics dosed prophylactically and therapeutically in established ‘disease’ conditions.
HDM sensitisation induced the production of total and specific IgE (Fig. 2 and Additional file 2: Figure S2). Decades of research have implicated IgE-mediated responses in asthma and IgE is now a key target for asthma therapy. However, some have argued that increases in measurable IgE could be merely a result of asthma i.e. a marker of inflammation . Additionally, studies utilising IgE directed therapy have shown mixed results . Thus, IgE independent mechanisms have been suggested to also contribute to allergic disease [13, 51, 52, 53]. Through the use of KO mice deficient in IgE and functional B cells, our findings suggest that, at least in this model, IgE and B cells are not required for the generation of immune responses in animals systemically sensitised with and topically exposed to HDM (Figs. 10 and 11). This is in accordance with the suggestion that HDM can contribute to allergic disease independent of IgE, but is in contrast with a recent publication showing that mice, deficient in B cells, repeatedly exposed to an allergenic cocktail of HDM, Alternaria and Aspergillus exhibited reduced airway inflammation, lung pathology and AHR . However, it is likely that the different allergens administered can act through different pathways some of which might indeed be independent of B cells and IgE production [55, 56, 57, 58]. Furthermore, existing experimental model data, in contrast to these observations, suggested that the role of B cells in allergen induced immune responses may depend on the route of allergen delivery and on the type of allergen used [54, 58]. This could account for the differences with our model and the divergent data regarding the role of B cells in the regulation of immune responses to various allergens. Moreover, we show that the airway inflammatory response and associated AHR in this model is T cell dependent as CD8+ and CD4+ T cell KO mice failed to develop a response distinguishable from WT saline exposed control mice (Figs. 8 and 9). In the clinic elevated numbers of lymphocytes correlate with eosinophilia and asthma severity and this lymphocytosis has been shown to include both CD4+ and CD8+ T cells [59, 60, 61]. The CD4+ T cell is thought to be the dominant active T cell subtype in clinical allergic asthma as well as in animal models of asthma [57, 60, 62, 63, 64]. In contrast, the role of CD8+ T cells both in human asthma and animal models of allergic disease remains controversial, having been reported to be both protective or deleterious . Supporting our data however, an increase in airway CD8+ T cells following allergen challenge predicts annual FEV1 decline in asthmatic patients [66, 67] and increased numbers can be found in patients following a fatal asthma attack [68, 69].
It is clear from published experimental data that CD4+ and CD8+ T cells can contribute to AHR development and allergic inflammation. However, the interpretation of their role and importance during sensitisation and/or challenge across various different models can vary largely. It is well established that CD4+ T cells are required during sensitisation [57, 70, 71]. Reconstitution of CD4+ T cells alone in RAG-/- mice, deficient in both T-and B-cells, prior to sensitisation was sufficient for Aspergillus fumigatus-induced AHR and airway inflammation . Interestingly, while CD8+ T cells were not required, this observation was also dependent on IL-4. Additionally, CD4+ T cell depletion before allergen challenge resulted in reduced AHR and airway eosinophilia  suggesting they are indeed crucial for the development of allergen induced airway disease. CD8+ T cells can differentiate, under the right conditions, in separate subsets [72, 73, 74, 75]. It has been argued that these different subsets within different models could be responsible for the contradictory reports. Specific depletion of CD8+ T cells in sensitised rats enhanced the airway inflammation and related late asthmatic responses  and in addition augmented airway remodelling and mucus production. [77, 78]. Similarly, certain CD8+ T cell subsets have been shown to prevent OVA-induced inflammation in mice [79, 80]. Others have shown that CD4+, but not CD8+ T cells are required for allergic airway responses [57, 81]. In contrast, a body of work by Gelfand and colleagues [70, 71, 82, 83] using mainly a systemic sensitisation and topical challenge OVA mouse model of allergic asthma corroborates our results in this HDM model and highlights a role for both CD8+ and CD4+ T cells in AHR and airway inflammation. Using a variety of adoptive cell transfer studies and KO mice, they demonstrated the activation of allergen primed CD8+ T cells and IL-13 production within the airway [71, 83] critical for AHR and airway inflammation in this model. Additionally, their data suggest that CD4+ T cells and IL-4 are crucial during sensitisation for CD8+ T cell activation . More recent publications also highlighted a possible role for IL-13 producing CD8+ T cell populations in augmented allergen driven inflammatory responses even in the absence of prior sensitisation . It would be interesting to see whether similar pathways underlie the AHR and airway inflammation in our HDM model and merits further investigation. It is likely that a close interaction between CD4+ and CD8+ T cells is key to driving the allergic responses within our HDM model.
In summary, we have developed a murine model of allergic asthma characterised by allergic airway inflammation and AHR which is dependent on prior allergen sensitisation without the need for an exogenous adjuvant. We show that this inflammation and AHR is dependent on CD4+ and CD8+ T cells and is persistent following multiple challenges. Our data reinforce the notion that T cells play a pivotal role in orchestrating pathological and physiological changes observed in human asthma. This newly developed model holds advantage over models that utilise topical administration in isolation in that sensitisation and challenge phases can be easily distinguished which allows separate interrogation. Additionally, with the possibility of repeat challenges this model could be useful in studies exploring therapeutic interventions in established chronic disease.
Sources of support
Studies were supported by the Medical Research Council; (MRC, UK) (MR/K020293/1). KB was supported by an MRC studentship.
- 4.Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005–2009. Natl Health Stat Rep. 2011;32:1–14.Google Scholar
- 8.Swirski FK, Gajewska BU, Alvarez D, Ritz SA, Cundall MJ, Cates EC, Coyle AJ, Gutierrez-Ramos JC, Inman MD, Jordana M, Stampfli MR. Inhalation of a harmless antigen (ovalbumin) elicits immune activation but divergent immunoglobulin and cytokine activities in mice. Clin Exp Allergy. 2002;32:411–21.CrossRefPubMedGoogle Scholar
- 22.Adam E, Hansen KK, Astudillo Fernandez O, Coulon L, Bex F, Duhant X, Jaumotte E, Hollenberg MD, Jacquet A. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J Biol Chem. 2006;281:6910–23.CrossRefPubMedGoogle Scholar
- 25.Asokananthan N, Graham PT, Stewart DJ, Bakker AJ, Eidne KA, Thompson PJ, Stewart GA. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J Immunol. 2002;169:4572–8.CrossRefPubMedGoogle Scholar
- 32.Schramm CM, Puddington L, Wu C, Guernsey L, Gharaee-Kermani M, Phan SH, Thrall RS. Chronic inhaled ovalbumin exposure induces antigen-dependent but not antigen-specific inhalational tolerance in a murine model of allergic airway disease. Am J Pathol. 2004;164:295–304.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Hagendorens MM, Ebo DG, Bridts CH, Van de Water L, De Clerck LS, Stevens WJ. Prenatal exposure to house dust mite allergen (Der p 1), cord blood T cell phenotype and cytokine production and atopic dermatitis during the first year of life. Pediatr Allergy Immunol. 2004;15:308–15.CrossRefPubMedGoogle Scholar
- 61.Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, Larche M, Robinson DS, Durham SR, Kay AB. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol. 1997;158:3539–44.PubMedGoogle Scholar
- 63.Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J Allergy Clin Immunol. 1993;92:313–24.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.